|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
How Is Accelerate Diagnostics Positioned at the Start of 2018? In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock. As a result of the offering, the cash position of the company increased to $121.3 million at the end of 3Q17 as compared with $77.8 million at the end of 3Q16.
Baxter's (BAX) Arisure Closed System reduces exposure risk of healthcare professionals to needles. Also, the latest development promotes safe handling of hazardous drugs.
How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.
Tuscon-based Accelerate Diagnostics (AXDX) is a diagnostics company focused on developing solutions and tools to provide rapid diagnostic results. While results from traditional culture-based tests usually take two to three days, Accelerate’s technology platform is built to deliver substantially faster and more accurate testing of infectious pathogens. The platform is intended to rapidly diagnose infectious pathogens.
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.
Stryker's 52-Week High: Should You Expect Further Upside?SYK stock at 52-week high On January 9, Stryker (SYK) traded at a 52-week high of $164.2 per share. The stock ended trading with a closing price of $160.4. As of January 9, 2018, SYK stock is trading higher than its 50-day moving average of $155 as well as the 200-day moving average of $148.1. Stryker traded at a 52-week low of $117.6 on January 9, 2017. The company’s one-year stock return is ~35% as of January 9, 2018.
Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.
The U.S. is facing a nationwide shortage of intravenous bags because of production woes linked to the Puerto Rico hurricane, forcing many hospitals to use more time-consuming ways to administer drugs.
Baxter International Inc (NYSE:BAX) generated a below-average return on equity of 11.31% in the past 12 months, while its industry returned 13.25%. An investor may attribute an inferior ROE toRead More...